文章摘要
邵美丽,王少丽,王林林,张 华,吉 婷,靳海涛.TP化疗后奥拉帕利维持治疗对晚期卵巢癌患者近远期疗效、安全性和血清肿瘤标志物的影响[J].,2023,(24):4710-4714
TP化疗后奥拉帕利维持治疗对晚期卵巢癌患者近远期疗效、安全性和血清肿瘤标志物的影响
Effects of Olaparide Maintenance Therapy after TP Chemotherapy on Short Term and Long Term Efficacy, Safety and Serum Tumor Markers in Patients with Advanced Ovarian Cancer
投稿时间:2023-05-23  修订日期:2023-06-19
DOI:10.13241/j.cnki.pmb.2023.24.022
中文关键词: 奥拉帕利  晚期卵巢癌  TP化疗  近远期疗效  肿瘤标志物
英文关键词: Olapali  Advanced ovarian cancer  TP chemotherapy  Short term and long-term efficacy  Tumor markers
基金项目:陕西省科学技术厅重点研发计划项目(2022SF-27;72018SF-078)
作者单位
邵美丽 西北妇女儿童医院妇产科 陕西 西安 710038 
王少丽 西北妇女儿童医院妇产科 陕西 西安 710038 
王林林 西北妇女儿童医院妇产科 陕西 西安 710038 
张 华 西北妇女儿童医院妇产科 陕西 西安 710038 
吉 婷 西北妇女儿童医院妇产科 陕西 西安 710038 
靳海涛 西安交通大学第一附属医院东院肿瘤内科 陕西 西安 710089 
摘要点击次数: 40
全文下载次数: 39
中文摘要:
      摘要 目的:探讨紫杉醇+顺铂方案(TP)化疗后应用奥拉帕利维持治疗对晚期卵巢癌患者近远期疗效、安全性和血清肿瘤标志物水平的影响。方法:选择2019年6月至2020年12月期间我院收治的78例晚期卵巢癌患者作为研究对象,分为对照组和观察组,41例和37例。所有患者均行TP化疗,观察组在化疗后接受奥拉帕利维持治疗。比较两组化疗后6个月时的临床疗效和癌症患者生活质量核心问卷(EORTCQLQ-C30)评分、化疗后2年内的无进展生存期和总生存期以及治疗过程中的不良反应发生情况。比较两组患者化疗前和化疗后6个月时血清癌抗原125(CA125)、特异性组织多肽抗原(TPS)、癌抗原199(CA199)、人附睾蛋白4(HE4)水平。结果:(1)观察组患者ORR(64.86% vs. 41.46%)和DCR(83.78% vs. 60.98%)均显著高于对照组(P<0.05);(2)观察组化疗后6个月时的自EORTCQLQ-C30评分明显高于对照组(P<0.05);(3)观察组化疗后6个月时血清CA125、TPS、CA199和HE水平均显著低于对照组(P<0.05);(4)观察组中位PFS和OS分别为8.000(95%CI:7.151~8.849)和15.000(95%CI:13.505~16.495),均显著大于对照组(P<0.05);(5)两组骨髓抑制、胃肠道反应、肝功能损伤、肾功能损伤和心脏毒性等毒副反应发生率比较均无显著差异(P>0.05)。结论:TP化疗后应用奥拉帕利能够提高晚期卵巢癌患者近期疗效,延长生存时间,改善生存质量,安全性高。
英文摘要:
      ABSTRACT Objective: To investigate the short-term and long-term efficacy, safety and serum tumor marker levels of patients with advanced ovarian cancer treated with olapari after chemotherapy with paclitaxel plus cisplatin (TP). Methods: 78 patients with advanced ovarian cancer admitted to our hospital from January 2019 to December 2020 were selected as the research subjects. They were divided into a matched group and an observation group based on different treatment plans, with 41 patients and 37 patients in each group. All patients received TP chemotherapy, and the observation group received olapari maintenance treatment after chemotherapy. Compare the clinical efficacy and EORTCQLQ-C30 scores of cancer patients at 6 months after chemotherapy between two groups, as well as the progression free survival and overall survival within 2 years after chemotherapy, and the incidence of adverse reactions during the treatment process. Compare the serum levels of cancer antigen 125 (CA125), specific tissue peptide antigen (TPS), cancer antigen 199 (CA199), and human epididymal protein 4 (HE4) between two groups of patients before and 6 months after chemotherapy. Results: (1) The ORR (64.86% vs. 41.46%) and DCR (83.78% vs. 60.98%) of the observation group were higher than those of the matched group (P<0.05); (2) The self EORTCQLQ-C30 score of the observation group at 6 months after chemotherapy was higher than that of the matched group (P<0.05); (3) At 6 months after chemotherapy, the serum levels of CA125, TPS, CA199, and HE in the observation group were lower than those in the matched group (P<0.05); (4) The median PFS and OS in the observation group were 8.000 (95%CI: 7.151~8.849) and 15.000 (95%CI: 13.505~16.495), respectively, which were higher than those in the matched group (P<0.05); (5) There was no difference between the two groups in the incidence of Bone marrow suppression, gastrointestinal reaction, liver function injury, renal function injury and cardiac toxicity(P>0.05). Conclusion: The application of olapari after TP chemotherapy can improve the short-term efficacy of patients with advanced ovarian cancer, prolong the survival time, improve the quality of life, and have high safety.
查看全文   查看/发表评论  下载PDF阅读器
关闭